2.551 - 2.575 of 34.477
- Product
- Maturity
- Leverage (Omega)
- Sell
- Buy
- Novo Nordisk Call 405,00 19 Jun 2026
- Goldman Sachs
- 19.06.26
- 4,14x
- Analysis
- Novo Nordisk Call 435,00 19 Jun 2026
- Goldman Sachs
- 19.06.26
- 4,32x
- Analysis
- Novo Nordisk Call 285,00 19 Jun 2026
- Goldman Sachs
- 19.06.26
- 2,82x
- Analysis
- Novo Nordisk Call 265,00 19 Jun 2026
- Goldman Sachs
- 19.06.26
- 2,57x
- Analysis
- Novo Nordisk Call 405,00 20 Mar 2026
- Goldman Sachs
- 20.03.26
- 4,48x
- Analysis
- Novo Nordisk Call 275,00 19 Jun 2026
- Goldman Sachs
- 19.06.26
- 2,69x
- Analysis
- Novo Nordisk Call 535,00 20 Mar 2026
- Goldman Sachs
- 20.03.26
- 5,35x
- Analysis
- Novo Nordisk Call 375,00 20 Mar 2026
- Goldman Sachs
- 20.03.26
- 4,08x
- Analysis
- Novo Nordisk Call 485,00 20 Mar 2026
- Goldman Sachs
- 20.03.26
- 4,95x
- Analysis
- Novo Nordisk Call 305,00 19 Jun 2026
- Goldman Sachs
- 19.06.26
- 3,04x
- Analysis
- Novo Nordisk Call 315,00 19 Jun 2026
- Goldman Sachs
- 19.06.26
- 3,18x
- Analysis
- Novo Nordisk Call 515,00 20 Mar 2026
- Goldman Sachs
- 20.03.26
- 5,16x
- Analysis
- Novo Nordisk Call 295,00 19 Jun 2026
- Goldman Sachs
- 19.06.26
- 2,94x
- Analysis
- Novo Nordisk Call 455,00 20 Mar 2026
- Goldman Sachs
- 20.03.26
- 4,90x
- Analysis
- Novo Nordisk Call 315,00 20 Mar 2026
- Goldman Sachs
- 20.03.26
- 3,34x
- Analysis
- Novo Nordisk Call 415,00 20 Mar 2026
- Goldman Sachs
- 20.03.26
- 4,55x
- Analysis
- Novo Nordisk Call 525,00 20 Mar 2026
- Goldman Sachs
- 20.03.26
- 5,28x
- Analysis
- Novo Nordisk Call 425,00 19 Jun 2026
- Goldman Sachs
- 19.06.26
- 4,23x
- Analysis
- Novo Nordisk Call 505,00 19 Sep 2025
- Goldman Sachs
- 19.09.25
- 9,91x
- Analysis
- Novo Nordisk Call 445,00 20 Mar 2026
- Goldman Sachs
- 20.03.26
- 4,72x
- Analysis
- Novo Nordisk Call 505,00 20 Mar 2026
- Goldman Sachs
- 20.03.26
- 5,07x
- Analysis
- Novo Nordisk Call 365,00 20 Mar 2026
- Goldman Sachs
- 20.03.26
- 3,99x
- Analysis
- Novo Nordisk Call 335,00 20 Mar 2026
- Goldman Sachs
- 20.03.26
- 3,58x
- Analysis
- Novo Nordisk Call 345,00 20 Mar 2026
- Goldman Sachs
- 20.03.26
- 3,71x
- Analysis
- Novo Nordisk Call 305,00 20 Mar 2026
- Goldman Sachs
- 20.03.26
- 3,20x
- Analysis